Bristol-Myers Squibb Company (BMY)
Largest Insider Buys in Sector
BMY Stock Price History Chart
BMY Stock Performance
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Insider Activity of Bristol-Myers Squibb Company
Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $672,994 and sold $1.15M worth of Bristol-Myers Squibb Company stock.
On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $4.22M and sold $36.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Samuels Theodore R. II (director) — $1.27M. BOERNER CHRISTOPHER S. (Chief Executive Officer) — $249,609.
The last purchase of 2,000 shares for transaction amount of $99,560 was made by BOERNER CHRISTOPHER S. (Chief Executive Officer) on 2023‑12‑05.
List of Insider Buy and Sell Transactions, Bristol-Myers Squibb Company
| 2023-12-05 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $49.78 | $99,560 | -0.89% | ||
| 2023-11-28 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 3,071 0.0002% | $48.86 | $150,049 | +1.92% | ||
| 2023-11-20 | Samuels Theodore R. II | director | 8,500 0.0004% | $49.81 | $423,385 | +1.61% | ||
| 2023-08-24 | Sale | Powell Ann | EVP, Chief Human Resources | 17,986 0.0009% | $61.25 | $1.1M | -17.24% | |
| 2023-08-03 | Sale | Plenge Robert M | EVP, Chief Research Officer | 732 <0.0001% | $61.14 | $44,754 | -16.61% | |
| 2023-05-03 | Sale | VESSEY RUPERT | EVP & President, Research | 50,385 0.0024% | $67.06 | $3.38M | -19.35% | |
| 2023-02-06 | Sale | Caforio Giovanni | Board Chair and CEO | 240,000 0.0115% | $74.65 | $17.92M | -15.58% | |
| 2023-02-06 | Sale | Powell Ann | EVP, Chief Human Resources | 11,183 0.0005% | $74.69 | $835,258 | -15.58% | |
| 2022-11-09 | Sale | Powell Ann | EVP, Chief Human Resources | 16,250 0.0008% | $80.45 | $1.31M | -15.55% | |
| 2022-11-07 | Sale | VESSEY RUPERT | EVP, Research & Early Dev. | 45,910 0.0022% | $78.88 | $3.62M | -14.63% | |
| 2022-09-20 | Sale | Caforio Giovanni | Board Chair and CEO | 25,000 0.0012% | $69.71 | $1.74M | +0.62% | |
| 2022-09-15 | Sale | Caforio Giovanni | Board Chair and CEO | 50,000 0.0023% | $71.84 | $3.59M | -2.19% | |
| 2022-09-14 | Sale | Powell Ann | EVP, Chief Human Resources | 25,000 0.0012% | $70.75 | $1.77M | -0.31% | |
| 2022-09-13 | Sale | Elkins David V | EVP, Chief Financial Officer | 133,951 0.0063% | $71.30 | $9.55M | -1.02% | |
| 2022-06-13 | Sale | Caforio Giovanni | Board Chair and CEO | 30,000 0.0014% | $74.04 | $2.22M | -0.89% | |
| 2022-06-06 | Sale | LEUNG SANDRA | EVP, General Counsel | 65,000 0.003% | $74.89 | $4.87M | -2.93% | |
| 2022-03-21 | Sale | Caforio Giovanni | Board Chair and CEO | 25,000 0.0012% | $71.52 | $1.79M | +5.53% | |
| 2022-03-16 | Sale | VESSEY RUPERT | EVP, Research & Early Dev. | 31,331 0.0015% | $69.27 | $2.17M | +7.64% | |
| 2022-03-14 | Sale | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | 29,532 0.0014% | $69.20 | $2.04M | +8.29% | |
| 2022-03-14 | Sale | Santiago Karen Murphy | SVP & Controller | 6,577 0.0003% | $69.19 | $455,096 | +8.29% |
Insider Historical Profitability
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 82672 0.0041% | $42.50 | 2 | 1 | |
| Samuels Theodore R. II | director | 35500 0.0017% | $42.50 | 5 | 0 | +8.25% |
| Powell Ann | EVP, Chief Human Resources | 27868 0.0014% | $42.50 | 0 | 5 | |
| Plenge Robert M | EVP, Chief Research Officer | 6584 0.0003% | $42.50 | 0 | 1 | |
| CELGENE CORP /DE/ | 10 percent owner | 7008510 0.3444% | $42.50 | 1 | 1 | +6.23% |
| ANDREOTTI LAMBERTO | director | 935571 0.046% | $42.50 | 0 | 43 | |
| HOOPER ANTHONY C | SVP ComOps Pres USJap Int | 530806 0.0261% | $42.50 | 0 | 2 | |
| LEUNG SANDRA | EVP, General Counsel | 308627 0.0152% | $42.50 | 0 | 10 | |
| Cuss Francis M | EVP & CSO | 266033 0.0131% | $42.50 | 0 | 5 | |
| Caforio Giovanni | Board Chair and CEO | 236104 0.0116% | $42.50 | 0 | 19 | |
| Celentano John E | SVP HR Public Affairs & Philan | 213556 0.0105% | $42.50 | 0 | 5 | |
| Carlo de Notaristefani | Pres Tech Ops & Supp Fnctns | 197745 0.0097% | $42.50 | 0 | 4 | |
| Bancroft Charles A | EVP & Chief Financial Officer | 184694 0.0091% | $42.50 | 0 | 5 | |
| Cazala Beatrice J | EVP Commercial Operations | 173375 0.0085% | $42.50 | 0 | 5 | |
| SIGAL ELLIOT | EVP, CSO & President R&D | 148221 0.0073% | $42.50 | 1 | 10 | +21.52% |
| CORNELIUS JAMES M | director | 119464 0.0059% | $42.50 | 2 | 116 | +5.54% |
| Elkins David V | EVP, Chief Financial Officer | 100460 0.0049% | $42.50 | 0 | 2 | |
| von Autenried Paul | EVP, Chief Information Officer | 63536 0.0031% | $42.50 | 0 | 10 | |
| Elicker John E | EVP, Investor Relations | 58666 0.0029% | $42.50 | 0 | 9 | |
| ZABOR DAVID L | VP Strat Bus Initiatives | 54670 0.0027% | $42.50 | 0 | 1 | |
| DANIELS BRIAN | SVP Global Dev & Med Affairs | 53549 0.0026% | $42.50 | 0 | 7 | |
| VESSEY RUPERT | EVP & President, Research | 47751 0.0023% | $42.50 | 0 | 9 | |
| Caldarella Joseph C | SVP & Controller | 46297 0.0023% | $42.50 | 0 | 15 | |
| SKULE JOHN L III | SVP, Corp & Envirn Affairs | 39857 0.002% | $42.50 | 0 | 2 | |
| Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | 31956 0.0016% | $42.50 | 0 | 11 | |
| Moed Samuel J | SVP, Strat Plan & Analysis | 31015 0.0015% | $42.50 | 0 | 6 | |
| Nielsen Anne | Chief Compliance & Ethics Off | 28126 0.0014% | $42.50 | 0 | 1 | |
| Zito Robert T | SVP & Chief Comm Officer | 24016 0.0012% | $42.50 | 0 | 1 | |
| Huet Jean-Marc | EVP & CFO | 25000 0.0012% | $42.50 | 1 | 0 | +21.52% |
| MCBRIDE ANTHONY A | SVP Human Resources | 24637 0.0012% | $42.50 | 0 | 1 | |
| Paliwal Dinesh C | director | 22109 0.0011% | $42.50 | 2 | 0 | +7.67% |
| Santiago Karen Murphy | SVP & Controller | 16704 0.0008% | $42.50 | 0 | 2 | |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 13777 0.0007% | $42.50 | 0 | 5 | |
| BERTOLINI ROBERT J | director | 11397 0.0006% | $42.50 | 1 | 0 | +34.49% |
| Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | 9251 0.0005% | $42.50 | 0 | 1 | |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 8069 0.0004% | $42.50 | 0 | 2 | |
| BONNEY MICHAEL W | director | 7189 0.0004% | $42.50 | 1 | 0 | +5.24% |
| FUTTER ELLEN V | director | 4894 0.0002% | $42.50 | 0 | 1 | |
| GROBSTEIN MICHAEL | director | 3383 0.0002% | $42.50 | 2 | 1 | +5.44% |
| LACY ALAN J | director | 2305 0.0001% | $42.50 | 0 | 1 | |
| CAMPBELL LEWIS B | director | 0 0% | $42.50 | 0 | 5 | |
| GLIMCHER LAURIE H M.D. | director | 0 0% | $42.50 | 0 | 2 |
Institutional Investor Ownership
| The Vanguard Group | $10.09B | 9.18 | 186.07M | -6.1% | -$655.79M | 0.19 | |
| BlackRock | $8.82B | 8.02 | 162.56M | -3.3% | -$300.58M | 0.2 | |
| State Street | $4.97B | 4.52 | 91.57M | +2.38% | +$115.23M | 0.21 | |
| JPMorgan Chase | $4.82B | 4.38 | 88.81M | -1.37% | -$66.93M | 0.43 | |
| Capital International Investors | $3.81B | 3.46 | 70.2M | +14.1% | +$470.46M | 0.77 | |
| Charles Schwab | $2.91B | 2.65 | 53.72M | +372.78% | +$2.3B | 0.66 | |
| Fidelity Investments | $2.31B | 2.1 | 42.57M | -0.11% | -$2.56M | 0.16 | |
| Geode Capital Management | $2.23B | 2.04 | 41.3M | +4.1% | +$88.01M | 0.2 | |
| Morgan Stanley | $1.59B | 1.44 | 29.27M | -0.38% | -$6.07M | 0.12 | |
| PRIMECAP Management Co | $1.26B | 1.15 | 23.27M | -1.11% | -$14.15M | 0.95 | |
| Northern Trust | $1.25B | 1.14 | 23M | -4.19% | -$54.55M | 0.21 | |
| Bank of America | $1.13B | 1.03 | 20.89M | +0.79% | +$8.92M | 0.11 | |
| Ameriprise Financial | $1.07B | 0.98 | 19.76M | -28.76% | -$432.92M | 0.3 | |
| Legal & General | $1.05B | 0.95 | 19.33M | -2.44% | -$26.19M | 0.25 | |
| Invesco | $914.05M | 0.83 | 16.86M | +8.03% | +$67.95M | 0.19 | |
| BNY Mellon | $906M | 0.82 | 16.71M | -1.85% | -$17.12M | 0.17 | |
| Dimensional Fund Advisors | $903M | 0.82 | 16.65M | -1.82% | -$16.73M | 0.24 | |
| Dodge & Cox | $882.16M | 0.8 | 16.27M | +0.41% | +$3.62M | 0.51 | |
| Goldman Sachs | $866.14M | 0.79 | 15.97M | -2.37% | -$21.04M | 0.16 | |
| Independent Franchise Partners, LLP | $761.62M | 0.69 | 14.04M | -0.15% | -$1.13M | 6.3 | |
| T. Rowe Price | $680.47M | 0.62 | 12.55M | +77.08% | +$296.19M | 0.08 | |
| Voya Investment Management | $666.7M | 0.61 | 12.29M | +119.82% | +$363.4M | 2.29 | |
| Ubs Asset Management Americas Inc | $661.34M | 0.6 | 12.2M | +6.06% | +$37.78M | 0.24 | |
| Franklin Templeton Investments | $627.55M | 0.57 | 11.57M | +23.67% | +$120.11M | 0.19 | |
| Boston Partners | $560.54M | 0.51 | 10.4M | -24.47% | -$181.63M | 0.66 | |
| CalPERS | $540.32M | 0.49 | 9.96M | -2.39% | -$13.21M | 0.38 | |
| Nuveen | $539.56M | 0.49 | 9.95M | -7.06% | -$41M | 0.16 | |
| Wells Fargo | $510.44M | 0.46 | 9.41M | +22.01% | +$92.08M | 0.14 | |
| Pacer Advisors Inc | $496.04M | 0.45 | 9.15M | +16.8% | +$71.37M | 1.25 | |
| Two Sigma Advisers LP | $484.84M | 0.44 | 8.94M | +0.41% | +$1.99M | 0.83 | |
| LSV Asset Management | $462.7M | 0.42 | 8.53M | -2.33% | -$11.02M | 0.96 | |
| Deutsche Bank | $443.72M | 0.4 | 8.18M | -39.66% | -$291.65M | 0.2 | |
| Royal Bank of Canada | $432.31M | 0.39 | 7.97M | +16.74% | +$62M | 0.1 | |
| VanEck | $431.08M | 0.39 | 7.95M | +97.2% | +$212.49M | 0.66 | |
| Nordea Investment Management Ab | $416M | 0.38 | 7.69M | -30.84% | -$185.49M | 0.49 | |
| UBS | $413.07M | 0.38 | 7.62M | +56.35% | +$148.87M | 0.13 | |
| Barclays | $330.61M | 0.3 | 6.1M | -10.91% | -$40.48M | 0.15 | |
| Swiss National Bank | $330.45M | 0.3 | 6.09M | -6.72% | -$23.81M | 0.23 | |
| Amundi | $287.81M | 0.29 | 5.87M | +17.55% | +$42.97M | 0.12 | |
| HSBC | $293.32M | 0.27 | 5.41M | +18.31% | +$45.4M | 0.21 | |
| KBC Group | $287.18M | 0.26 | 5.3M | +85.98% | +$132.77M | 0.91 | |
| Sumitomo Mitsui Trust Holdings | $275.19M | 0.25 | 5.07M | -9.29% | -$28.18M | 0.19 | |
| Credit Suisse | $264.9M | 0.24 | 4.88M | -26.86% | -$97.28M | 0.24 | |
| Canada Pension Plan Investment Board | $262.02M | 0.24 | 4.83M | +7.23% | +$17.66M | 0.27 | |
| PNC Financial Services | $257.53M | 0.23 | 4.75M | -0.66% | -$1.71M | 0.18 | |
| Two Sigma | $249.31M | 0.23 | 4.6M | -6.13% | -$16.29M | 0.43 | |
| Schroder Investment Management Group | $247.96M | 0.23 | 4.57M | +31.92% | +$60M | 0.29 | |
| AllianceBernstein | $235.49M | 0.21 | 4.34M | +8.48% | +$18.41M | 0.08 | |
| Federated Hermes | $219.66M | 0.2 | 4.05M | +1,479.95% | +$205.76M | 0.51 | |
| Prudential Financial | $211.78M | 0.19 | 3.91M | +7.92% | +$15.54M | 0.3 |